These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 20536404)

  • 1. Spontaneous rupture of the liver in a patient with systemic AL amyloidosis undergoing treatment with high-dose melphalan and autologous stem cell transplantation: a case report with literature review.
    Tam M; Seldin DC; Forbes BM; Connors LH; Skinner M; Oran B; Quillen K; Sanchorawala V
    Amyloid; 2009; 16(2):103-7. PubMed ID: 20536404
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Short and long-term outcome of treatment with high-dose melphalan and stem cell transplantation for multiple myeloma-associated AL amyloidosis.
    Girnius S; Seldin DC; Skinner M; Finn KT; Quillen K; Doros G; Sanchorawala V
    Ann Hematol; 2010 Jun; 89(6):579-84. PubMed ID: 20012043
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosis.
    Sanchorawala V; Wright DG; Seldin DC; Dember LM; Finn K; Falk RH; Berk J; Quillen K; Skinner M
    Bone Marrow Transplant; 2001 Oct; 28(7):637-42. PubMed ID: 11704785
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Microbiologically documented infections in patients undergoing high-dose melphalan and autologous stem cell transplantation for the treatment of light chain amyloidosis.
    Taimur S; Nader C; Lloyd-Travaglini C; Seldin DC; Sanchorawala V
    Transpl Infect Dis; 2013 Apr; 15(2):187-94. PubMed ID: 23279695
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study.
    Skinner M; Sanchorawala V; Seldin DC; Dember LM; Falk RH; Berk JL; Anderson JJ; O'Hara C; Finn KT; Libbey CA; Wiesman J; Quillen K; Swan N; Wright DG
    Ann Intern Med; 2004 Jan; 140(2):85-93. PubMed ID: 14734330
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-Dose Melphalan and Stem Cell Transplantation in Patients on Dialysis Due to Immunoglobulin Light-Chain Amyloidosis and Monoclonal Immunoglobulin Deposition Disease.
    Batalini F; Econimo L; Quillen K; Sloan JM; Sarosiek S; Brauneis D; Havasi A; Stern L; Dember LM; Sanchorawala V
    Biol Blood Marrow Transplant; 2018 Jan; 24(1):127-132. PubMed ID: 28865972
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pre-transplantation novel agent induction predicts progression-free survival for patients with immunoglobulin light-chain amyloidosis undergoing high-dose melphalan and autologous stem cell transplantation.
    Cowan AJ; Klippel ZK; Stevenson PA; Hyun TS; Tuazon S; Becker PS; Green DJ; Holmberg LA; Coffey DG; Gopal AK; Libby EN
    Amyloid; 2016 Dec; 23(4):254-259. PubMed ID: 27879147
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Marked and rapid regression of hepatic amyloid deposition in a patient with systemic light chain (AL) amyloidosis after high-dose melphalan therapy with stem cell transplantation.
    Katoh N; Matsushima A; Kurozumi M; Matsuda M; Ikeda S
    Intern Med; 2014; 53(17):1991-5. PubMed ID: 25175136
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-dose melphalan with autologous stem cell transplantation after VAD induction chemotherapy for treatment of amyloid light chain amyloidosis: a single centre prospective phase II study.
    Perz JB; Schonland SO; Hundemer M; Kristen AV; Dengler TJ; Zeier M; Linke RP; Ho AD; Goldschmidt H
    Br J Haematol; 2004 Dec; 127(5):543-51. PubMed ID: 15566357
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ten-year follow-up after autologous stem cell transplantation of a patient with immunoglobulin light-chain (AL) amyloidosis with deposits in the heart, liver and gastrointestinal tract.
    Mejhert M; Hast R; Sandstedt B; Janczewska I
    BMJ Case Rep; 2011 Aug; 2011():. PubMed ID: 22688930
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Autologous stem-cell transplantation in progressing amyloidosis is associated with severe transplant-related toxicity.
    Worel N; Schulenburg A; Mitterbauer M; Keil F; Rabitsch W; Kalhs P; Gisslinger H; Raderer M; Geissler K; Höcker P; Zielinski CC; Oberbauer R; Greinix HT
    Wien Klin Wochenschr; 2006 Feb; 118(1-2):49-53. PubMed ID: 16489526
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modified High-Dose versus High-Dose Melphalan Conditioning in Older Patients Undergoing Autologous Stem Cell Transplantation for Immunoglobulin Light Chain Amyloidosis.
    Hassan H; Verma K; Ferri G; Brauneis D; Quillen K; Sloan JM; Sanchorawala V; Edwards CV
    Transplant Cell Ther; 2022 Nov; 28(11):761.e1-761.e7. PubMed ID: 35970300
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Spontaneous rupture of the spleen in AL amyloidosis.
    Oran B; Wright DG; Seldin DC; McAneny D; Skinner M; Sanchorawala V
    Am J Hematol; 2003 Oct; 74(2):131-5. PubMed ID: 14508801
    [TBL] [Abstract][Full Text] [Related]  

  • 14. How to treat patients with systemic amyloid light chain amyloidosis? Comparison of high-dose melphalan, low-dose chemotherapy and no chemotherapy in patients with or without cardiac amyloidosis.
    Hoshino J; Ubara Y; Sawa N; Sumida K; Hiramatsu R; Hasegawa E; Suwabe T; Hayami N; Yamanouchi M; Takemoto F; Taniguchi S; Takaichi K
    Clin Exp Nephrol; 2011 Aug; 15(4):486-92. PubMed ID: 21387097
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-dose melphalan and peripheral blood stem cell transplantation for light-chain amyloidosis with cardiac involvement.
    Madan S; Kumar SK; Dispenzieri A; Lacy MQ; Hayman SR; Buadi FK; Dingli D; Rajkumar SV; Hogan WJ; Leung N; Grogan M; Gertz MA
    Blood; 2012 Feb; 119(5):1117-22. PubMed ID: 22147893
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tandem cycles of high-dose melphalan and autologous stem cell transplantation increases the response rate in AL amyloidosis.
    Sanchorawala V; Wright DG; Quillen K; Finn KT; Dember LM; Berk JL; Doros G; Fisher C; Skinner M; Seldin DC
    Bone Marrow Transplant; 2007 Sep; 40(6):557-62. PubMed ID: 17589534
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modified High-Dose Melphalan and Autologous Stem Cell Transplantation for Immunoglobulin Light Chain Amyloidosis.
    Nguyen VP; Landau H; Quillen K; Brauneis D; Shelton AC; Mendelson L; Rahman H; Sloan JM; Sarosiek S; Sanchorawala V
    Biol Blood Marrow Transplant; 2018 Sep; 24(9):1823-1827. PubMed ID: 29933072
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induction Therapy with Bortezomib Followed by Bortezomib-High Dose Melphalan and Stem Cell Transplantation for Light Chain Amyloidosis: Results of a Prospective Clinical Trial.
    Sanchorawala V; Brauneis D; Shelton AC; Lo S; Sun F; Sloan JM; Quillen K; Seldin DC
    Biol Blood Marrow Transplant; 2015 Aug; 21(8):1445-51. PubMed ID: 25858810
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Amyloid deposits in the bone marrow of patients with immunoglobulin light chain amyloidosis do not impact stem cell mobilization or engraftment.
    Cowan AJ; Seldin DC; Skinner M; Quillen K; Doros G; Tan J; O'Hara C; Finn KT; Sanchorawala V
    Biol Blood Marrow Transplant; 2012 Dec; 18(12):1935-8. PubMed ID: 22842332
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-dose intravenous melphalan and autologous stem cell transplantation as initial therapy or following two cycles of oral chemotherapy for the treatment of AL amyloidosis: results of a prospective randomized trial.
    Sanchorawala V; Wright DG; Seldin DC; Falk RH; Finn KT; Dember LM; Berk JL; Quillen K; Anderson JJ; Comenzo RL; Skinner M
    Bone Marrow Transplant; 2004 Feb; 33(4):381-8. PubMed ID: 14676787
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.